Tomoya Mita
Overview
Explore the profile of Tomoya Mita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torimoto K, Okada Y, Mita T, Tanaka K, Sato F, Katakami N, et al.
J Diabetes
. 2025 Mar;
17(3):e70065.
PMID: 40049179
Aims: This study determined the association of the glycaemia risk index (GRI), a novel comprehensive metric derived from continuous glucose monitoring (CGM), and atherosclerosis in patients with type 2 diabetes...
2.
Katakami N, Mita T, Sato Y, Watada H, Shimomura I
Diabetol Int
. 2024 Aug;
15(3):379-388.
PMID: 39101158
Aims/introduction: The aim of the study was to evaluate the effects of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on circulating levels of hepatic enzymes, uric acid and hemoglobin levels...
3.
Sato J, Nakajima K, Mita T, Koshibu M, Sato A, Goto H, et al.
Diabetes Ther
. 2024 Feb;
15(4):883-892.
PMID: 38363542
Introduction: Recent studies have shown that the quality of life (QOL) of people living with type 1 diabetes (T1D) is poor and must be improved. However, the living situation and...
4.
Mita T
J Clin Endocrinol Metab
. 2024 Jan;
109(8):e1667-e1668.
PMID: 38227825
No abstract available.
5.
Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, et al.
Diabetologia
. 2023 Sep;
66(12):2356-2367.
PMID: 37750893
Aims/hypothesis: Previous studies have suggested that glucose variability may accelerate atherosclerosis progression in people with type 2 diabetes. Current guidelines recommend assessing glycaemic control using continuous glucose monitoring (CGM), which...
6.
Tomizawa N, Fujimoto S, Mita T, Takahashi D, Nozaki Y, Fan R, et al.
Radiol Cardiothorac Imaging
. 2023 Sep;
5(4):e230016.
PMID: 37693191
Purpose: To investigate whether vorticity could predict functional plaque progression better than high-risk plaque (HRP) and lesion length (LL) in individuals with type 2 diabetes mellitus. Materials And Methods: This...
7.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al.
Sci Rep
. 2023 Sep;
13(1):14649.
PMID: 37669959
We previously reported in the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) that alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid atherosclerosis in subjects...
8.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Cardiovasc Diabetol
. 2023 Jun;
22(1):143.
PMID: 37349722
Background: This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes...
9.
Bouchi R, Sugiyama T, Goto A, Ohsugi M, Yoshioka N, Katagiri H, et al.
J Diabetes Investig
. 2023 May;
14(8):994-1004.
PMID: 37183588
Aims/introduction: To investigate whether the COVID-19 pandemic affected behavioral changes and glycemic control in patients with diabetes and to conduct a survey of telemedicine during the pandemic. Materials And Methods:...
10.
Yoshii H, Mita T, Katakami N, Okada Y, Osonoi T, Aso K, et al.
J Clin Endocrinol Metab
. 2022 Jul;
107(10):e3990-e4003.
PMID: 35908248
Context: Current guidelines recommend assessing glycemic control using continuous glucose monitoring (CGM) and hemoglobin A1c (HbA1c) measurement. Objective: This study aimed to clarify the characteristics of patients who might benefit...